Coronavirus isn’t the only thing on FDA’s mind
Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.
Biosimilars
FDA clarifies biosimilar labeling, advertising guidelines
The FDA and FTC want to ensure companies don’t use anticompetitive practices to squash the biosimilar market.
Infographic | Global medicine spending predictions
A recent IQVIA report breaks down global medicine spending and eyes what lies ahead.
The next five years of pharma: Pricing, biosimilars, and specialty medicines
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
Pfizer lawsuit could clear path for biosimilars
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Sandoz lines up potential third-to-market Humira copy
Although if approved, it’s not likely to launch in the U.S. for quite some time.
Five things for pharma marketers to know: Wednesday, January 10, 2018
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
Five things for pharma marketers to know: Wednesday, December 20, 2017
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Five things for pharma marketers to know: Wednesday, November 22, 2017
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium’s Xtampza over Purdue’s OxyContin
Five things for pharma marketers to know: Wednesday, November 15, 2017
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
